Diligence memo · auto-generated · as of July 2, 2026
Pulmair Medical, Inc.
Pulmair Medical, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pulmair Medical, Inc. operates in Biotechnology, based in San Diego.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pulmair Medical, Inc. has raised $7.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.5M on 2019-07-16.
Most recent recorded round closed around 2019-07-16.
Valuation (modeled)modeled
Provath models Pulmair Medical, Inc. at approximately $271M (range $8.2M–$1.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.50× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 0 months.
Last raise 7.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 51% of Biotechnology peers (4293 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.